АЛЛОГЕННЫЙ БИОМАТЕРИАЛ – ИНГИБИТОР ФИБРОЗА В ИШЕМИЧЕСКИ ПОВРЕЖДЕННОМ МИОКАРДЕЛебедева, А.И.,
Гареев, Е.М.,
Афанасьев, С.А.,
Кондратьева, Д.С.,
Муслимов, С.А.,
Попов, С.В.,
Lebedeva, A.I.,
Gareev, E.M.,
Afanasiev, S.A.,
Kondratyeva, D.S.,
Muslimov, S.A.,
Popov, S.V. (2023) группе вводили физиологический раствор. Животных выводили из опыта на 3-и, 7-е,
14-е, 30-е, 45-е сутки
Bikbov, Mukharram M.,
Kazakbaeva, Gyulli M.,
Holz, Frank G.,
Panda-Jonas, Songhomitra,
Gilemzianova, Leisan I.,
Khakimov, Dinar A.,
Jonas, Jost B. (2023) (13.8±2.4 mm Hg vs
14.3±2.6 mm Hg; p=0.20) remained unchanged. In nine patients with a follow-up of >3
Gilyazova, Irina,
Ivanova, Elizaveta,
Sinelnikov, Mikhail,
Pavlov, Valentin,
Khusnutdinova, Elza,
Khusnutdinova, Elza,
Beilerli, Aferin,
Mikhaleva, Ludmila,
Liang, Yanchao (2023) regression model the high expression of miR-153 increased the risk of metastasis development (odds ratios = 3.
14Gilyazova, I.,
Ivanova, E.,
Pavlov, V.,
Khasanova, G.,
Khasanova, A.,
Izmailov, A.,
Asadullina, D.,
Gilyazova, G.,
Wang, G.,
Gareev, I.,
Beylerli, O. (2023) collected three times: during the initial febrile period (days
1–4 of
illness), the polyuric period (days 15
Bikbov, M.M.,
Kazakbaeva, G.M.,
Fakhretdinova, A.A.,
Tuliakova, A.M.,
Rakhimova, E.M.,
Panda-Jonas, S.,
Gilemzianova, L.I.,
Garipova, L.A.,
Khakimov, D.A.,
Jonas, J.B. (2023) 0.22mm (95%CI:-0.05,0.48), and (0.09mm (95%CI:-0.15,0.34) versus 0.
14mm (95%CI:0